The European Medicines Group (EMG) has appointed Sanofi’s Rippon Ubhi as its new chair.
Ubhi, who will maintain her position as country lead for Sanofi UK and Ireland, holds almost 20 years of senior commercial leadership experience in global, international and affiliate organisations, and has lived and worked in the UK, US and Japan over the past decade.
Prior to joining Sanofi, Ubhi spent 18 years in a variety of roles at AstraZeneca, first serving as medical sales representative for cardiovascular and respiratory in the UK and later as senior marketing director, respiratory business unit in the US. Her most recent role at AstraZeneca was global head of commercial strategy and portfolio, immuno-oncology franchise.
As chair of the EMG, which represents 22 continental European headquartered research-based pharmaceutical companies, Rippon will play a key role in shaping the group’s strategic direction and priorities.
She will lead efforts to advocate for policies that support the development and timely access to innovative medicines in the UK, and will focus on supporting initiatives that position the UK as a “world-leading base” for life sciences, Sanofi said.
Commenting on her latest appointment, Ubhi said: “This is a great opportunity to contribute to shaping the future of healthcare in the UK and to work towards our shared goal of improving patients’ lives.
“As chair, I will be working closely with EMG members, the government and NHS to make the UK a life sciences superpower which provides faster access to innovative medicines and vaccines, attracts inward investment, and drives economic growth.”